mbiomics reaches 30 million euros with third closing of Series A round
TechBio start-up develops oral microbiome therapeutics from living bacterial strains
Advertisement
mbiomics GmbH, a TechBio company developing scalable, microbiome-based therapeutics for severe and chronic diseases, announced the successful third closing of its Series A financing round of EUR 12 million, bringing the total volume of the round to EUR 30 million. Several existing investors, including MIG Fonds and Bayern Kapital, participated in the financing round.
The newly raised capital will be used to further strengthen the pharmacological data sets required for the approval of clinical trials (IND, Investigational New Drug) and to accelerate development and manufacturing according to GMP standards. At the same time, mbiomics is preparing for the clinical evaluation of its lead drug candidate MBX-116 as a combination therapy with an immune checkpoint inhibitor in advanced melanoma. The funding marks the company's transition from platform development to clinical translation and enables the further development of its Techbio platform towards scalable production and clinical application.
"Although the clinical potential of the gut microbiome is well understood, the translation of microbiome-based therapeutics into a scalable product remains a significant technical challenge. At mbiomics, we are solving this challenge by building the entire technology stack for development, analysis, screening and manufacturing of complex microbial consortia. Our focus is now on advancing our lead drug candidate MBX-116 into clinical trials," said Dr. Johannes B. Woehrstein, CEO and co-founder of mbiomics.
mbiomics develops live biotherapeutic products (LBPs). These are oral therapeutics consisting of live bacterial strains designed to restore the functional and metabolic potential of the gut microbiome in a scalable and pharmaceutical-grade manner. Fecal microbiota transplants (FMTs) have shown clinical efficacy in several indications, confirming microbiome modulation as a therapeutic strategy. This approach is inherently variable and not scalable. In contrast, mbiomics' proprietary platform enables the rational design of defined, large and complex microbial consortia. The platform combines AI/ML-assisted consortia design, proprietary analysis technologies, co-cultivation of large consortia and comprehensive screening capabilities.
Dr. Matthias Kromayer, Managing Partner at MIG Capital, commented: "We are pleased to continue to support mbiomics in this financing round. Since our first investment, the team has made impressive progress in translating insights from microbiome research into a scalable therapeutic approach. The company is close to entering clinical validation and continues to build its broad therapeutic pipeline with great momentum."
Clinical evidence from oncology has shown that modulation of the gut microbiome can significantly improve response rates to immune checkpoint inhibitors. On this basis, mbiomics is initially focusing on second-line treatment in advanced melanoma to evaluate the potential of its lead drug candidate MBX-116 as a combination therapy to improve treatment outcomes in this indication. The start of a Phase 1B trial is planned for 2027. Beyond oncology, the company is developing a broader pipeline of microbiome-based therapeutics with potential applications in other indications where the gut microbiome plays a central role, including autoimmune and neurodegenerative diseases.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.